Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary analysis.
J. D. Hainsworth
No relevant relationships to disclose
E. Arrowsmith
No relevant relationships to disclose
M. McCleod
No relevant relationships to disclose
L. Fayad
Research Funding - Lilly
O. Hamid
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
L. Davis
Research Funding - i3 Statprobe
B. K. Lin
Employment or Leadership Position - Lilly
Stock Ownership - Lilly